Prostate Cancer | Specialty

Treating High-Risk Localized Prostate Cancer

December 18th 2013

3D Transperineal Prostate Mapping Biopsies

December 18th 2013

Multiparametric MRI for Prostate Cancer Diagnosis

December 18th 2013

Case Study: Prostate Cancer Screening

December 18th 2013

Melbourne Consensus Statement on PSA Screening

December 18th 2013

Introduction: The AUA PSA Screening Guidelines

December 18th 2013

Cooperberg Discusses New Drugs in Prostate Cancer

December 17th 2013

This year's approval of radium-223 chloride (Xofigo) continues the 4-year run of important new prostate cancer drugs, and Matthew Cooperberg thinks the run will continue over the next few years.

PCPT Trial Helps Confirm Role of 5α-Reductase Inhibitors in Prostate Cancer Prevention

December 17th 2013

Two years after the FDA denied a request to expand the indication of finasteride and other 5α-reductase inhibitors to prevent prostate cancer, a major study has cast doubt on the concerns that prompted the denial: that the drug raised the risk of more lethal cancers.

Predicting Risk of Aggressive Prostate Cancer Through Biomarkers in Blood

December 16th 2013

A new study has shown a possible correlation between men with short-ended chromosomes in the immune cells of their blood and an increased risk of developing aggressive prostate cancer, potentially pointing the way toward an accessible biomarker that could help inform treatment and surveillance decisions.

Dr. Kelly on Selecting Therapy for Patients with CRPC

November 27th 2013

William Kevin Kelly, DO, professor of medical oncology and urology, Thomas Jefferson University, discusses the possibility of preselecting which castration-resistant prostate cancer (CRPC) patients will be sensitive to chemotherapy or hormone therapy.

Dr. Sawyers Accepts his "Giants of Cancer Care" Award

November 21st 2013

Charles L. Sawyers, MD, Chair, Human Oncology and Pathogenesis Program; Marie-Josee and Henry R. Kravis Chair, Memorial Sloan-Kettering Cancer Center, accepts the Giants of Cancer Care Award for his work in prostate cancer.

Urologist Ownership of Imaging Centers Affects Self-Referral Rates

November 14th 2013

Urologists who treat men with prostate cancer are 2.5 times more likely to refer patients to intensity-modulated radiation therapy centers, especially if they have a financial stake in the IMRT center.

Dr. Yu on the Role of PET Imaging in Prostate Cancer

November 14th 2013

Evan Y. Yu, MD, associate professor, Department of Medicine, Division of Oncology, Seattle Cancer Care Alliance, discusses the role of PET imaging in prostate cancer.

Molecular Signature Distinguishes Indolent From Aggressive Prostate Cancer

November 8th 2013

Prostate cancer is one of the most common forms of cancer in older men, with more than 200,000 new diagnoses per year.

In Advanced Prostate Cancer, Degarelix Offers Advantages Over LHRH Agonists

October 31st 2013

Men with advanced prostate cancer who took the GnRH antagonist degarelix experienced improved disease control, fewer instances of urinary infections, and a lower risk of cardiovascular events than did those patients who took LHRH agonists.

Pre-Chemo Trial of Enzalutamide Halted After Meeting Endpoints

October 22nd 2013

The phase III PREVAIL trial of enzalutamide in chemotherapy-naïve patients with advanced prostate cancer has been stopped early after meeting its co-primary endpoints of overall survival and radiographic progression-free survival

Epigenetic Variations in Prostate Tumors May Determine Choice Between Definitive Treatment and Active Surveillance

October 16th 2013

Prostate cancer is the most common cancer and second leading cause of cancer mortality in American men. Nevertheless, it is estimated that only 3% of the patients will die because of their cancer, while the majority will die of competing causes.

Abiraterone Stalls Pain, Quality of Life Decline in mCRPC

October 11th 2013

Abiraterone acetate significantly delayed the progression of pain and quality of life deterioration in chemotherapy-naive men with metastatic castration-resistant prostate cancer when taken in combination with prednisone.

First Approved Alpha Emitter Bolsters Arsenal Against Prostate Cancer

October 10th 2013

With the recent approval of a first-in-class radioactive isotope as a treatment for prostate cancer, urologists have a new weapon in their rapidly growing arsenal of therapies designed to fight this disease.

Biomarkers Predict Prognosis for Patients With mCRPC

October 3rd 2013

A new biomarker panel taken 12 weeks after initiating treatment with abiraterone acetate plus prednisone can predict prognosis at 2 years in men with metastatic castration-resistant prostate cancer